Why the study?
Athletes with cardiac channelopathies were historically excluded from participation under blanket restrictions despite an absence of data, whereas newer scientific evidence now informs decision making for these heterogeneous conditions.
These guidelines transition the management of athletes with cardiac channelopathies from historical blanket exclusions toward a shared decision-making model for return to play following expert evaluation, risk stratification, and treatment.
Answers are grounded in this paper and cite their sources.
May support return to play for athletes with channelopathies through shared decision-making; challenges historical blanket disqualification policies.
Cardiac channelopathies, including long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, Brugada syndrome, and short QT syndrome, are heterogeneous conditions, which can lead to varying risks in athletes depending on their symptoms, disease severity, genotype, and therapies initiated. Historically, athletes with these conditions were excluded from participation with blanket restrictions, despite an absence of data. More recently, a number of studies have provided more scientific evidence to guide decision making and have been incorporated into these guidelines for athletes with cardiac channelopathies. Many athletes with these conditions may be supported in their decision to return to play as part of a shared decision-making model when they have been assessed, risk stratified, and appropriately treated by a specialist with expertise in these conditions.
No takes yet. Share an insight, caveat, or question.
Gray et al. (2026) studied Cardiac channelopathies (long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, Brugada syndrome, and short QT syndrome) in athletes. Shared decision-making model with specialist assessment, risk stratification, and appropriate treatment vs. Blanket exclusion/restrictions from athletic participation was evaluated on Return to play / athletic participation. Shared decision-making alongside specialist evaluation, risk stratification, and appropriate therapy can support return to play for many athletes with cardiac channelopathies.
Synapse has enriched 10 related papers. Consider them for comparative context: